To examine the effects of heparin on smooth muscle cells (SMCs) in explants of varicose, long saphenous vein (LSV).
Procedures:
Explants of varicose LSV were cultured for 7 days either alone, or with heparin at 10, 100 or 1000 IU/ml (Monoparin). At 7 days, cultured explants were analysed for changes in intimal and medial thickness and by immuno-histochemistry. Comparisons were made with explants at initial isolation and with similar, cultured explants of normal LSV.
Results:
In normal LSV, by day 7, SMC-derived neo-intimal hyperplasia developed (p<0.01) with an increase in intimal thickness (p<0.02) and a decrease in medial thickness (p<0.001). Heparin at 10 and 100 IU/ml further enhanced this neo-intima formation (p<0.001). In contrast, at 1000 IU/ml, heparin inhibited neo-intima formation. In varicose explants, the pattern of intimal and medial changes was different. At isolation, varicose LSVs had substantially thicker intimal layers (p<0.001). When cultured alone, a thicker media developed (p<0.001) but there was little change in intimal thickness. Heparin at all concentrations had no effect on the thicker medial development seen in controls but did, however, reduce intimal thickness (p<0.005).
Conclusions:
The response to heparin in explants of varicose LSV is different from that of normal LSV, which is biphasic and complex.
ThulesiusOUgaily-ThulusiusLGjoresJENeglenP.The varicose saphenous vein: Functional and ultrastructural studies, with special reference to smooth muscle. Phleblogy1988; 3: 89–95.
2.
TraversJPDaltonCMBakerDMMakinGS. Biochemical and histological analysis of collagen and elastin content and smooth muscle density in normal and varicose veins. Phlebology1992; 7: 92–100.
3.
RoseSSAhmedA.Some thoughts on the aetiology of varicose veins. J Cardiovasc Surg1986; 27: 534–43.
4.
ObitsuYIshimaruSFurukawaKYoshimaraI.Histopathological studies of the valves of varicose veins. Phlebology1990; 5: 245–54.
5.
BrowseNLBurnandKGIrvineATWilsonNM. Diseases of the veins, 2nd ed.London: Edward Arnold, 1999:145–62.
6.
ThulesiusOGjoresJE. Reactions of venous smooth muscle in normal men and patients with varicose veins. Angiology1974; 25: 145–54.
7.
LayerGTPattisonMEvansBDaviesDRBurnandKG. Tissue fibrinolytic activity is reduced in varicose veins. In: NegusDJantetG, editors. Phlebology '85. London: John Libbey, 1986.
8.
UrbanovaDPrerovskyI.Enzymes in the wall of normal and varicose veins: Histochemical study. Angiologia1972; 9: 53–61.
9.
WolfeJHNMorlandMBrowseNL. The fibrinolytic activity of varicose veins. Br J Surg1979; 66: 185–7.
10.
ShiremanPKMcCarthyWJPearceWHShivelyVPCipolloneMKwaanHC, Plasminogen activator levels are influenced by location and varicosity in greater saphenous vein. J Vasc Surg1996; 24: 719–24.
11.
KreyselHWNissenHPEnghoferE.A possible role of lysosomal enzymes in the pathogenesis of varicosis and the reduction in their serum activity by Venostasin. Vasa1983; 12: 377–82.
12.
HayerMCaporiccioAPagesACaporiccioGToueriMFde BornierB. MagnanLysosomal enzymes and severity of saphen varicosis. Clin Chim Acta1991; 203: 343–8.
13.
RefsonJSSchachterMPatelMKHughesADMunroEChanP, Vein graft stenosis and the heparin responsiveness of human vascular smooth muscle cells. Circulation1998; 97: 2506–10.
14.
HollingsworthSJTangCBBarkerSGE. An in vitro model for the molecular investigation of varicose veins: Use of cultured explants of human long saphenous vein. Phlebology2001; 16/2:53–59.
15.
SoyomboAAAngeliniGDBryanAJJasaniBNewbyAC. Intimal proliferation in an organ culture of human saphenous vein. Am J Pathol1990; 137: 1401–10.
16.
PorterKEVartyKJonesLBellPRLondonNL. Human saphenous vein organ culture: A useful model of intimal hyperplasia?Eur J Vasc Endovasc Surg1996;11: 48–58.
17.
TrendelenburgF.Ueber die Unterbindung der Vena saphena magna bei unterschenkel Varicen. Beitr Klin Chir1890–1; 7: 195–210.
18.
HollingsworthSJTangCBBarkerSGE. Primary varicose veins in the presence of an intact sapheno-femoral junction. Presented at Venous Forum, Royal Society of Medicine, Chester Meeting, October 2000. Phlebology2001; 16/2:68–72
KlagsbrunMEdelmanER. Biological and biochemical properties of fibroblast growth factors: Implications for the pathogenesis of atherosclerosis. Atherosclerosis1989; 9: 269–78.
21.
BurgessWHMaciagT.The heparin-binding (fibroblast) growth factor family of proteins. Annu Rev Biochem1989; 58: 575–606.
22.
MedalionBMerinGAingornHMiaoHQNaglerAElamiA, Endogenous basic fibroblast growth factor displaced by heparin from the luminal surface of human blood vessels is preferentially sequestered by injured regions of the vessel wall. Circulation1997; 95: 1853–62.
23.
LindnerVLappiDABairdAMajackRAReidyMA. Role of basic fibroblast growth factor in vascular lesion formation. Circ Res1991; 68: 106–13.
24.
LindnerVReidyMA. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci USA1991; 88: 3739–43.
25.
ReillyCFFritzeLMRosenbergRD. Heparin-like molecules regulate the number of epidermal growth factor receptors on vascular smooth muscle cells. J Cell Physiol1988; 136: 23–32.
26.
FagerGCamejoGBondjersG.Heparin-like glycosaminoglycans influence growth and phenotype of human arterial smooth muscle cells in vitro. I. Evidence for reversible binding and inactivation of the platelet-derived growth factor by heparin. In Vitro Cell Dev Biol1992; 28A;168–75.
27.
LindnerVOlsonNEClowesAWReidyMA. Inhibition of smooth muscle cell proliferation in injured rat arteries: Interaction of heparin with basic fibroblast growth factor. J Clin Invest1992; 90: 2044–49.
28.
McCaffreyTAFalconeDJBraytonCFAgarwalLAWeltFGWekslerBB. Transforming growth factor-beta activity is potentiated by heparin via dissociation of the transforming growth factor-beta/alpha 2-macroglobulin inactive complex. J Cell Biol1989; 109: 441–48.
29.
WrightTCJrPukacLACastellotJJJrKarnovskyMJLevineRAKim-ParkHY, Heparin suppresses the induction of c-fos and c-myc mRNA in murine fibroblasts by selective inhibition of a protein kinase C-dependent pathway. Proc Natl Acad Sci USA1989; 86: 3199–203.
30.
HedinUDaumGClowesAW. Heparin inhibits thrombin-induced mitogen-activated protein kinase signalling in arterial smooth muscle cells. J Vasc Surg1998; 27: 512–20.
31.
HerbertJMClowesMLeaHJPascalMClowesAW. Protein kinase C alpha expression is required for heparin inhibition of rat smooth muscle cell proliferation in vitro and in vivo. J Biol Chem1996; 271: 25928–35.
32.
CastellotJJJrPukacLACalebBLWrightTCJrKarnovskyMJ. Heparin selectively inhibits a protein kinase C-dependent mechanism of cell cycle progression in calf aortic smooth muscle cells. J Cell Biol1989; 109: 3147–55.
33.
MajeskyMWSchwartzSMClowesMMClowesAW. Heparin regulates smooth muscle S phase entry in the injured rat carotid artery. Circ Res1987; 61: 296–300.
34.
ReillyCFKindyMSBrownKERosenbergRDSonensheinGE. Heparin prevents vascular smooth muscle cell progression through the G1 phase of the cell cycle. J Biol Chem1989; 264: 6990–5.
35.
KenagyRDClowesAW. Regulation of baboon arterial smooth muscle cell plasminogen activators by heparin and growth factors. Thromb Res1995; 77: 55–61.
